Postdoc at @UMNews | Passionate about GU Oncology | Royal College of Surgeons alumnus | Interested in proteogenomics and liquid biopsies 🇪🇬🇺🇸
We profiled extracellular vesicles in plasma and identified proteins associated with treatment outcomes in men with advanced prostate cancer treated with 177Lu-PSMA-617. This work would not have been possible without the mentorship and guidance of @EAntonarakis@DrJustinDrake
Congrats @aliarafaa and @DrJustinDrake for your elegant work on plasma extracellular vesicle (EV) proteomics in Pluvicto-treated prostate cancer patients. Blood-based detection of PSMA, B7-H3, STEAP1 and Trop2 will help precision therapeutics! @UMNCancercell.com/cell-reports-medici…
Excited to share our prostate cancer proteomics work, initially presented at #ASCO25, is now featured on @VuMedi! Grateful for the chance to share how liquid biopsy biomarkers may help shape the future of personalized therapy. @UMNCancer@MPaT_PHCL_UMNvumedi.com/video/ascor-2025-…
ATM mutated tumors lack TP53 mutations, while gBRCA1-mutated tumors were enriched for TP53, suggesting synthetic essentiality. ATM-dependent cancers rely on intact TP53, opening new therapeutic vulnerabilities. Disrupting TP53 or inhibiting ATM could unlock targeted treatments!🚀
Largest study of BRCA-associated cancers (24,309) shows that somatic tumor landscape is influenced by germline HRR muts: gBRCA1-altered cancers are enriched in somatic TP53 muts; gATM-altered cancers are depleted in TP53 mut. Congrats @aliarafaa@umncanceraacrjournals.org/clincancerr…
I am really grateful for my mentors, @EAntonarakis@DrJustinDrake for their support and guidance! A huge thank you to the American Cancer Society @ACS_Research for funding my fellowship! 2025 and 2026 will be great for blood based proteomics!
Congrats @aliarafaa for developing a new method for robust plasma exosome proteomics capable of detecting and quantifying >5000 proteins incl. PSMA, B7H3, TROP2 and STEAP1. A new blood-based biomarker is born! @UMNewsmdpi.com/2072-6694/16/24/426…
Our multi-omics study highlights the unique biology of AMPC, a potential precursor to NEPC, with implications for early therapeutic targeting. FOXA1 and OTX2 may play crucial roles! @DrJustinDrake@EAntonarakis@MPaT_PHCL_UMN@UMNCancer
Congratulations to new @AmericanCancer postdoctoral fellow, @aliarafaa. His project addresses an important clinical problem - identifying biomarkers of response to Pluvicto among men receiving treatment for castration resistant metastatic prostate cancer. Thank you and good luck!
Congrats @aliarafaa for delivering your first Oral ASCO Abstract. Your impactful study shows that germline mutations clearly influence somatic mutation landscapes in BRCA-associated cancers. ascopubs.org/doi/abs/10.1200…
Stoked for our ASCO poster showing NK cell infiltration and survival benefit across numerous solid tumors. NK cells are coming for you prostate cancer!
Abstr 10509: Largest study examining the somatic genomic landscape of tumors developing in germline HRR mutation carriers versus sporadic cancers. Congrats @aliarafaa for your first ASCO Oral presentation. Thanks to @TempusLabs for this rich data set. meetings.asco.org/abstracts-…
Humbled to be featured in the March/April edition of Prostatepedia @NASPCC1. I had the opportunity to discuss the impact of the PSMA PET scan on clinical decision-making, current clinical trials, biomarkers, and targeted therapies.
online.flippingbook.com/view…
Extremely honored to announce that my very first
@ASCO abstract has been accepted for an oral presentation as part of a clinical science symposium! I am very grateful for the mentorship and guidance of
@EAntonarakis. Thank you @TempusLabs for making this happen!! #ASCO23